Daiichi, ArQule’s struggling tivantinib fails in phase 3 liver cancer test

The pair have seen a series of setbacks over the years for the med.

After fluffing its lines in two mid-to-late stage trials in lung and colorectal cancer over the past few years, Daiichi and ArQule had hoped that tivantinib could produce the goods in a phase 3 liver cancer test, but it was not to be.

In data released this morning, the partners said their MET-inhibitor med did not meet its primary endpoint of improving overall survival in hepatocellular carcinoma (the most common form of liver cancer) in 340 patients.

The trial, dubbed METIV-HCC, was set up as a biomarker-selected, double-blind, placebo-controlled, phase 3 study that looked at tivantinib against best supportive care in patients with MET-overexpressing, inoperable HCC who cannot take, or were previously treated, with systemic therapy.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

The primary endpoint of the study was overall survival, but the pair said in a brief update that it did not meet this target, although detailed data on how much is missed by were not published in the release.

Secondary endpoints included progression-free survival and safety, but again no data were given. The pair said more information will be shared “an upcoming scientific forum.”

“HCC is a disease with high unmet need, especially in the second-line setting, so these results are disappointing for the patients as well as the investigators and the companies,” said Paolo Pucci, CEO of ArQule.

“Despite the negative outcome of this study, we remain committed to applying rigorous science to unmet needs for patients with cancer,” added Antoine Yver, MD, EVP and global head of oncology R&D at Daiichi Sankyo.

The company has seen a string of negative results for this drug, but there was a ray of light in late 2014, when it posted a positive outcome in a phase 2 metastatic prostate cancer study after hitting the primary endpoint for progression-free survival compared to a placebo.

But this has not helped relieve pressure from the biotech, and this latest setback will only ramp up the questions on the drug’s clinical future across the board. The biotech's shares were down more than 4% yesterday, before the news, at less than $1.50 a share and with a market cap of $111 million. 

Daiichi, which trades in Japan, was down 0.5% today on the data. The company has been swinging the R&D ax of late, cutting down research sites in Japan, India, the U.K. and Germany, but has also been keen to pen new cancer R&D pacts, most recently with Kite Pharma and its potential first-to-market CAR-T candidate. 

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.